Author contribution:
AM proposed using bortezomib and wrote the text, UP, IK, DF, DB and NK
provided clinical care and data retrieval, EK provided plasma exchange,
PA assayed ADAMTS13 activity and anti-ADAMTS 13 inhibitors titres, GN
participated in discussion and provided valuable advices about paper
final version.
References
- Joly BS, Stepanian A, Leblanc T, et al. Child-onset and
adolescent-onset acquired thrombotic thrombocytopenic purpura with
severe ADAMTS13 deficiency: a cohort study of the French national
registry for thrombotic microangiopathy. Lancet Haematol .
2016;3(11):e537-e546. doi:10.1016/S2352-3026(16)30125-9
- Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13
antibodies as markers for recurrence of acquired thrombotic
thrombocytopenic purpura during remission. Haematologica .
2008;93(2):232-239. doi:10.3324/haematol.11739
- Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving
protease in thrombotic thrombocytopenic purpura and the
hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578-1584.
doi:10.1056/NEJM199811263392202
- Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving
protease in acute thrombotic thrombocytopenic purpura. N Engl J Med.
1998;339(22):1585-1594. doi:10.1056/NEJM199811263392203
- Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange
with plasma infusion in the treatment of thrombotic thrombocytopenic
purpura. Canadian Apheresis Study Group. N Engl J Med.
1991;325(6):393-397. doi:10.1056/NEJM199108083250604
- Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and
prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic
thrombocytopenic purpura: a study of 11 cases. Blood.
2005;106(6):1932-1937. doi:10.1182/blood-2005-03-0848
- Jestin M, Benhamou Y, Schelpe AS, et al. Preemptive rituximab prevents
long-term relapses in immune-mediated thrombotic thrombocytopenic
purpura. Blood . 2018;132(20):2143-2153.
doi:10.1182/blood-2018-04-840090
- Scully M. Rituximab in the treatment of TTP. Hematology. 2012;17 Suppl
1:S22-S24. doi:10.1179/102453312X13336169155178
- Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab Treatment for
Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med .
2019;380(4):335-346. doi:10.1056/NEJMoa1806311
- Jin M, Casper TC, Cataland SR, et al. Relationship between ADAMTS13
activity in clinical remission and the risk of TTP relapse. Br J
Haematol . 2008;141(5):651-658. doi:10.1111/j.1365-2141.2008.07107.x
- Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in
thrombotic thrombocytopenic purpura. N Engl J Med.
2013;368(1):90-92.doi:10.1056/NEJMc1213206
- Patriquin CJ, Thomas MR, Dutt T, et al. Bortezomib in the treatment of
refractory thrombotic thrombocytopenic purpura. Br J Haematol.
2016;173(5):779-785. doi:10.1111/bjh.13993
- Hernández Lorente E, Lluch García R, Monteagudo Santolaya E.
Effectiveness of bortezomib in the treatment of thrombotic
thrombocytopenic purpura: Case report. Efectividad del bortezomib en
el tratamiento de la púrpura trombótica trombocitopénica: descripción
de un caso. Med Clin (Barc). 2019;152(6):244-245.
doi:10.1016/j.medcli.2018.06.002
- Mazepa MA, Raval JS, Moll S, Ma A, Park YA. Bortezomib induces
clinical remission and reduction of ADAMTS13 inhibitory antibodies in
relapsed refractory idiopathic thrombotic thrombocytopenic purpura. Br
J Haematol. 2014;164(6):900-902. doi:10.1111/bjh.12696
- van Balen T, Schreuder MF, de Jong H, van de Kar NC. Refractory
thrombotic thrombocytopenic purpura in a 16-year-old girl: successful
treatment with bortezomib. Eur J Haematol . 2014;92(1):80-82.
doi:10.1111/ejh.12206
Figure 1.
Therapies delivered and evolution of laboratory parameters of patient 1.
Solid line indicates platelet counts, dash line depicts ADAMTS13
activity. PEX and arrows indicate plasma exchanges, R with white
arrowheads indicate rituximab, M followed by circles indicate high-dose
methylprednisolone, and B with black arrowheads indicate bortezomib.
Figure 2.
Therapies delivered and evolution of laboratory parameters of patient 1.
Solid line indicates platelet counts, dash line depicts ADAMTS13
activity. PEX and arrows indicate plasma exchanges, R with white
arrowheads indicate rituximab, M followed by circles indicate high-dose
methylprednisolone, and B with black arrowheads indicate bortezomib.